ourses > 130th Annual Shattuck Lecture (2020) - CRISPR: Rewriting DNA and the Future of Medicine

• Interim Meeting Educational Programs
• Conference and Webinar Calendar
• Live CME Events
• Online CME
• CME FAQs
• Joint Providership
• CME Accreditation for Institutions
• Conference Proceeding Archive
• My CME Credits
• Boston Medical Library

130th Annual Shattuck Lecture (2020) - CRISPR: Rewriting DNA and the Future of Medicine

130th Annual Shattuck Lecture (2020) - CRISPR: Rewriting DNA and the Future of Medicine

View the 130th Annual Shattuck Lecture without AMA PRA Category 1 Credit^TM.

Video Only
 

To earn AMA PRA Category 1 Credit^TM, proceed to the bottom and choose the purchase button.

Course Overview
The 130th Annual Shattuck Lecture, presented by Dr. Jennifer Doudna and moderated by Dr. Eric Rubin, focuses on how the role of bacteria in fighting viral infections uncovered CRISPR-Cas proteins that detect and cut specific DNA or RNA sequences. Current research in genome editing and the development of CRISPR-based diagnostics technology to address the current pandemic and beyond is also discussed.

Faculty

Jennifer A. Doudna, PhD

Li Ka Shing Chancellor’s Chair; Professor, Departments of Chemistry and Molecular and Cell Biology, University of California, Berkeley

Dr. Doudna is the Li Ka Shing Chancellor’s Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley. Her groundbreaking development of CRISPR-Cas9 as a genome-engineering technology, with collaborator Emmanuelle Charpentier, earned the two the 2020 Nobel Prize in Chemistry and forever changed the course of human and agricultural genomics research.

This powerful technology enables scientists to change DNA — the code of life — with a precision only dreamed of just a few years ago. Labs worldwide have re-directed the course of their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine.

In addition to her scientific achievements, Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies, and advocates for thoughtful approaches to the development of policies around the safe use of CRISPR technology. Doudna is an investigator with the Howard Hughes Medical Institute, senior investigator at Gladstone Institutes, and the President of the Innovative Genomics Institute. She co-founded and serves on the advisory panel of several companies that use CRISPR technology in unique ways.

She is a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, and the American Academy of Arts and Sciences. Doudna is also a Foreign Member of the Royal Society and has received numerous other honors including the Breakthrough Prize in Life Sciences (2015), the Japan Prize (2016), Kavli Prize (2018), the LUI Che Woo Welfare Betterment Prize (2019), and the Wolf Prize in Medicine (2020). Doudna’s work led TIME to recognize her as one of the “100 Most Influential People” in 2015 and a runner-up for “Person of the Year” in 2016. She is the co-author of “A Crack in Creation,” a personal account of her research and the societal and ethical implications of gene editing.

Eric J. Rubin, MD, PhD

Editor-in-Chief, New England Journal of Medicine, NEJM Group

Dr. Rubin joined the New England Journal of Medicine (NEJM) and NEJM Group as Editor-in-Chief in September 2019, taking on the responsibility for oversight of all editorial content and policies.

Dr. Rubin is an Associate Physician specializing in infectious disease at Brigham and Women’s Hospital and is a Professor in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. He serves on several scientific advisory boards to groups interested in infectious disease therapeutics. Dr. Rubin has also previously served as the Associate Editor for Infectious Disease at the New England Journal of Medicine as well as an editor for several basic science journals including PLoS Pathogens, Tuberculosis, and mBio.

Intended Audience
This activity is designed for physicians, scientists, researchers, and other health care professionals.

Course Objectives

• Describe how CRISPR-Cas systems function in bacteria.
• Explain how CRISPR systems are used for genome editing.
• Identify and evaluate applications of CRISPR-based genome editing.
   

Course Fees
Massachusetts Medical Society (MMS) Physician Member: $20.00
MMS Resident/Student Member: Free
Non-Member Physician: $45.00
Non-Members Resident/Student: $10.00
Allied Health Professional/Other: $16.00

Format & Estimated Time to Complete: Video, 1 hour

Accreditation Statement
Accreditation and Credit Information
The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Massachusetts Medical Society designates this internet enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Approval Statement
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, this activity has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

Allergy and Immunology
Anesthesiology
Colon and Rectal Surgery
Family Medicine
Medical Genetics and Genomics
Nuclear Medicine
Physical Medicine and Rehabilitation
Plastic Surgery
Preventive Medicine
Psychiatry and Neurology
Radiology
Thoracic Surgery
Urology

National Commission on Certification of Physicians Assistant (NCCPA)
Physician Assistants may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.